• We make diagnostics that matter
  • Medical Affairs
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • Subscribe, it’s free!
  • Search
  • Menu Menu
Clinical Laboratory int.
  • Biochemistry
  • Chemistry
  • Clinical
  • Clinical Biology
  • Laboratory
  • Management
  • Microbiology
  • Parasitology
  • Pathology
  • Research
  • Virology

Archive for category: E-News

E-News

Scherm­afbeelding 2023 09 14 om 12.31.32

Imaging breakthrough: speckle diffraction tomography reveals nanoscale features in thick biological specimens

, 14 September 2023/in E-News /by panglobal

For years, capturing detailed three-dimensional images of complex biological specimens has posed a major challenge due to their intricate composition and the multiple scattering of light. A game-changing moment has arrived, as scientists from the MIT Laser Biomedical Research Center and the Chinese University of Hong Kong have introduced an innovative method called speckle diffraction […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/09/Scherm­afbeelding-2023-09-14-om-12.31.32.jpg 951 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-09-14 10:32:552023-09-14 10:32:55Imaging breakthrough: speckle diffraction tomography reveals nanoscale features in thick biological specimens
Clovibactin structure

New antibiotic from microbial ‘dark matter’ could be powerful killer of superbugs

, 14 September 2023/in E-News /by panglobal

A powerful new antibiotic, isolated from bacteria that could not be studied before, seems capable of combatting harmful bacteria and multi-drug resistant ‘superbugs’. Named Clovibactin, the antibiotic appears to kill bacteria in an unusual way, making it more difficult for bacteria to develop resistance against it.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/09/Clovibactin_structure.png 895 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-09-14 10:28:122023-09-14 10:28:12New antibiotic from microbial ‘dark matter’ could be powerful killer of superbugs
Scherm­afbeelding 2023 09 14 om 12.20.34

EMA recommends authorisation of first RSV vaccine for infants

, 14 September 2023/in E-News /by panglobal

The European Medicines Agency (EMA) has recommended granting a marketing authorisation in the European Union (EU) for Pfizer Europe’s Abrysvo ( EMA opinion on Abrysvo: https://bit.ly/45jVL7Z ), a vaccine to protect against disease caused by the respiratory syncytial virus (RSV). Abrysvo is the first RSV vaccine indicated for passive immunisation of infants from birth through […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/09/Scherm­afbeelding-2023-09-14-om-12.20.34.png 517 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-09-14 10:23:222023-09-14 10:40:11EMA recommends authorisation of first RSV vaccine for infants
Scherm­afbeelding 2023 09 14 om 12.15.35

UK Health Security Agency opens advanced Vaccine Development and Evaluation Centre

, 14 September 2023/in E-News /by panglobal

UK Health Security Agency opens advanced Vaccine Development and Evaluation Centre

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/09/Scherm­afbeelding-2023-09-14-om-12.15.35.png 276 502 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-09-14 10:17:432023-09-14 10:17:43UK Health Security Agency opens advanced Vaccine Development and Evaluation Centre
shutterstock 1414691426

Tillotts Pharma and TVM Capital Life Science form Mage Biologics to develop oral antibody therapy for ulcerative colitis

, 13 September 2023/in E-News /by panglobal

TVM Capital Life Science, a leading international venture capital firm focused on investments in life sciences innovation, together with specialty pharma company, Tillotts Pharma, will jointly invest up to US$28 million in the newly formed U.S.-based biotechnology company, Mage Biologics. TVM will invest with its fund TVM Life Science Innovation II SCSp (TVM LSI II) […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/09/shutterstock_1414691426.jpg 1440 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-09-13 08:35:592023-09-13 08:35:59Tillotts Pharma and TVM Capital Life Science form Mage Biologics to develop oral antibody therapy for ulcerative colitis
Scherm­afbeelding 2023 09 13 om 10.30.05

Exothera to manufacture Meissa Vaccines’ paediatric RSV vaccine candidate for Phase 2 trials

, 13 September 2023/in E-News /by panglobal

Meissa Vaccines, a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, has entered into a manufacturing agreement with Exothera, a Univercells company and full-service Contract Research Development and Manufacturing Organization (CRDMO). Exothera delivers customized process development and GMP manufacturing services for vaccines, viral vectors and nucleic acids. Under the agreement, Exothera will manufacture […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/09/Scherm­afbeelding-2023-09-13-om-10.30.05.png 342 1256 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-09-13 08:31:262023-09-13 08:31:26Exothera to manufacture Meissa Vaccines’ paediatric RSV vaccine candidate for Phase 2 trials
1 DLOC Biosystems HOC assembly testing 9242

DLOC partners with 42 Technology to develop ‘human-on-chip’ system

, 13 September 2023/in E-News /by panglobal

DLOC Biosystems (DLOC), a spin-out from the American University of Beirut, has appointed UK-based 42 Technology (42T) as a strategic product development partner to help bring its advanced 3D human-on-chip technology and fully-automated operating system to market.

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/09/1_DLOC-Biosystems_HOC-assembly-testing_9242.jpg 1800 1800 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-09-13 08:27:422023-09-13 08:27:42DLOC partners with 42 Technology to develop ‘human-on-chip’ system
shutterstock 1758056162

NK:IO raises more funding to advance pioneering NK cell therapy

, 13 September 2023/in E-News /by panglobal

NK:IO, a leader in natural killer (NK) cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumours, has raised £1.2 million (about US$1.5 million). This brings total equity financing to £3.2 million and will enable the company to reach key milestones in progressing its differentiated NK cell therapy candidates into […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/09/shutterstock_1758056162.jpg 1080 1920 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-09-13 08:19:172023-09-13 08:19:17NK:IO raises more funding to advance pioneering NK cell therapy
Samanta Cimitan CEO

Celonic Group appoints new CEO

, 13 September 2023/in E-News /by panglobal

Celonic Group, a Swiss-based Biologics Contract Development and Manufacturing Organization (CDMO), has appointed Dr Samanta Cimitan as the Chief Executive Officer (CEO) of the Celonic Group, a subsidiary of the independent and privately owned J. Rettenmaier & Söhne Company (JRS Group).

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2023/09/Samanta_Cimitan_CEO.jpg 620 594 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-09-13 08:17:092023-09-13 08:17:09Celonic Group appoints new CEO

Evotec signs 3-year agreement for unlimited use of Titian Software’s Mosaic Sample Management Platform

, 13 September 2023/in E-News /by panglobal

Titian Software, a global leader in life sciences sample management software, and the life science company Evotec have signed a three-year agreement to expand their collaboration around Titian Software’s Mosaic Sample Management Platform. Mosaic forms part of Evotec’s plans to expand and harmonise sample management throughout the organisation, underpinning its expanding services. The new agreement […]

Read more
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 panglobal https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png panglobal2023-09-13 08:14:332023-09-13 08:14:33Evotec signs 3-year agreement for unlimited use of Titian Software’s Mosaic Sample Management Platform
Page 1 of 196123›»
Medical Affairs

Latest issue of Clinical laboratory

Company Profile Edition

CLi Cover CompanyProfileEdition
22 September 2023

NGS made effortless: introducing MIRO CANVAS from INTEGRA Biosciences

20 September 2023

Beck Automation presents a high-precision IML solution for medical applications at Fakuma 2023

15 September 2023

KAPPA and LAMBDA assays, in serum and urine, for nephelometers and clinical chemistry analyzers

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The leading international magazine for Clinical laboratory Equipment for everyone in the Vitro diagnostics

Sign up today
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
clinlab logo blackbg 1

Hastelweg 250
5652 CN Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com

PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only